Objectives: Invasive fungal disease (IFD) remains a major concern in patients with haematological conditions. We describe diagnoses, therapeutic management and outcomes in unselected consecutive patients from haematological facilities treated for suspected or documented IFD.
Introduction
Invasive fungal disease (IFD) remains a major concern in patients with haematological conditions, especially in those with chemotherapy-induced neutropenia or in recipients of haematopoietic stem cell transplantation (HSCT). Several recent changes were observed in the epidemiology of IFD, 1 -4 and outcomes have improved in haematological patients. 5 -7 These changes may be due to an evolution in the management of underlying conditions or to the availability of a widened antifungal arsenal, but also to a shift in practice towards early antifungal therapy. 8 -11 Although a lot of work has been devoted to IFD in the last 20 years, many studies have focussed on selected highrisk patients or on specific fungal agents. The purpose of this work was to describe diagnoses, therapeutic management and outcomes in unselected consecutive patients from haematological facilities treated for suspected or documented IFD.
Patients and methods
This was an observational prospective study. French haematological centres, including all those performing one or more HSCT per month, were offered participation. Patients were children or adults with haematological conditions or HSCT therapy. They were recruited upon start of nonprophylactic systemic antifungal treatment and followed-up thereafter for 12 weeks. No other selection criterion was applied. Written informed consent was obtained from all patients or their parents. Assent was given by children old enough to understand. In accordance with French law, Ethics Committee approval was not required as the protocol was strictly observational and usual practice was unchanged; approvals from the national review boards Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé and Commission nationale de l'informatique et des libertés were obtained.
Medical histories, haematological conditions and recent or ongoing treatments were collected at inclusion. Clinical signs, imaging and microbiological results and antifungal treatments were recorded retrospectively at inclusion and prospectively throughout the follow-up. Clinical evolution was recorded 6 and 12 weeks after inclusion. Cause of death was judged by the investigators. All data were recorded through a secure online case-report form. Independent monitoring was provided by a contract research organization during the whole study period.
Study documents and data collection were designed with pre-coded answers matching the IFD criteria definitions published in 2002 by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus group, and also the revised criteria published in 2008 but made available before publication to allow public comment. 12 -14 IFD episodes were subsequently classified by an expert committee according to the 2008 criteria 13 upon initiation of treatment (day 0) and 1 week later (day 7). All diagnostic procedures performed up to the given day were taken into account, regardless of the availability of their results at that date. The decision to limit this evaluation to the first 7 days was motivated by a desire to avoid confusion between the original episode and a subsequent IFD episode.
Episodes insufficiently documented to be classified as possible, probable or proven IFD were labelled febrile neutropenia where persistent fever and neutrophil count below 0.5×10 9 cells/L were the only grounds for suspecting an IFD, or unclassified episodes if these criteria were not satisfied (e.g. no severe neutropenia) or if other signs were reported but did not meet the criteria for possible IFD.
Mortality rates were determined using Kaplan-Meier estimates, and groups were compared using the log rank test. A Cox regression multivariate analysis was performed to identify prognostic factors for death in this population among the following selected variables: sex, age, mechanical ventilation, aspergillosis/mould infection, candidiasis/yeast infection, amphotericin B at day 0, combination therapy at day 0, azole agents at day 0, caspofungin at day 0, neutropenia (,0.5×10 9 cells/L), low creatinine clearance (,50 mL/min), malignancy status, antifungal prophylaxis, allogeneic HSCT, autologous HSCT and possible IFD at day 7. All analyses were carried out using SAS 9.2 (SAS Institute Inc., Cary, NC, USA).
Results

Patients
Of the 81 French haematological facilities invited to participate, 41 accepted, of which 37 included 419 patients (298 adults and 121 children) between December 2007 and December 2008. Two of these patients experienced two IFD episodes during the study period, and one experienced three episodes. Thus 423 episodes are described.
The characteristics of the patients are summarized in Table 1 . Most patients (88%) were treated for haematological malignancies, and 40 (10%) and 74 (18%) were recipients of autologous or allogeneic HSCT, respectively. Neutropenia (,0.5×10 9 cells/L) was present at day 0 in 284 patients (68%), and had lasted .10 days in 222 patients (53%). Overall, 184 patients (44%) were receiving antifungal prophylaxis at the time of the episode, reported as fluconazole (148/261 treatments, 57%), posaconazole (49/261, 19%), amphotericin B (32/261, 12%), voriconazole (13/261, 5%), itraconazole (12/261, 5%) or caspofungin (4/261, 2%). Prophylactic treatment was administered either orally or intravenously, in approximately equal amounts. Antifungal prophylaxis was used in 27 of the 48 proven infections (56%) as follows: fluconazole in 16 cases, amphotericin B in 5 cases, voriconazole in 3 cases and posaconazole in 3 cases.
IFD diagnoses
IFD diagnoses are shown in Table 2 , while species identified in proven infections are detailed in Table 3 . Proven and probable aspergilloses were the most common IFD classifications, representing 12.5% of the episodes (53/423) at day 0. Invasive candidiasis accounted for 7% of the episodes (29/423), while 59% of mycologically documented episodes (53/90) were invasive aspergillosis, diagnosed in most cases by detection of galactomannan antigen in serum or bronchoalveolar lavage fluid, and 32% (29/90) were invasive candidiasis. All Candida infections were proven by isolation of Candida species from blood cultures in 28 cases, from biopsy material in 4 cases and from peritoneal fluid in the remaining 3 cases. Fifty-nine percent of episodes (249/423) did not meet EORTC/MSG criteria for possible, probable or proven IFD. This rate was as high as 77% (93/121) in children at day 0.
Antifungal therapy
Initial and day 7 antifungal therapy received by patients is detailed in Table 4 . Combination therapy was given for 61 (14%) episodes at day 0, mostly in patients with febrile neutropenia, unclassified episodes or possible IFD. This high number of combination therapies may be explained in part by continuation of antifungal prophylaxis after day 0 in 40 patients. In nine patients, this prophylaxis was still ongoing at day 7. Antifungal therapy was changed before day 7 in 159 patients (38%). Over the 12 week follow-up, it was changed once or more in 49% of patients. Treatment change was more frequent in patients with probable or proven aspergillosis (median, two changes per patient) compared with patients with possible IFD, proven candidiasis or probable/proven other IFD (one change per patient); there were no changes in the remaining patients.
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Overall, median treatment duration was 29 days: 15 days for patients with febrile neutropenia, 23 days for unclassified episodes, 68 days for possible IFD, 32 days for proven candidiasis, and .12 weeks for probable or proven aspergillosis.
Mortality
Before week 12, 41 patients died. Of these, 12 (29%; 9 before week 6) were considered related to IFD by investigators. Most of the other deaths were related to the underlying haematological condition and/or to bacterial infections. The 12 week mortality rate was 3% for febrile neutropenia, 12% for unclassified episodes, 9% for possible IFD, 18% for probable/proven aspergillosis, 15% for proven candidiasis and 10% for probable/proven other IFD (log rank P ¼ 0.016, Figure 1) . Out of 10 patients with other IFD, 1 with a proven Rhodotorula mucilaginosa infection died at week 10 from his underlying condition.
Multivariate analysis for risk factors associated with a higher mortality in the overall population showed that older age [hazard ratio (HR) 1.4/10 years; 95% CI 1.2-1.7; P,0.001], absence of underlying malignancy remission at antifungal therapy onset (HR 5.3; 95% CI 1.6-17.5; P ¼ 0.007) and mechanical ventilation at antifungal therapy onset (HR 2.8; 95% CI 1.1 -7.1; P¼ 0.037) were significant determinants of mortality. 
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Discussion
This work provides a comprehensive picture of patients treated for a suspected or documented IFD with their treatments and outcomes, in a large number of haematological facilities, across the whole French territory. Only 47% of these episodes met the criteria for possible, probable or proven IFD according to EORTC/MSG criteria by day 7 of antifungal treatment. More than half of the other episodes could be classified as febrile neutropenia since they had persistent fever, neutrophil count ,0.5×10 9 cells/L and no other clinical or mycological sign of IFD, matching this well-defined condition in haematological patients. Although many haematology departments have developed various preemptive strategies, it is still widely accepted that these patients should receive empirical antifungal treatment after failure of broad-spectrum antibiotherapy. 15 Several clinical trials have been conducted to assess such empirical antifungal therapies and have led to the approval of liposomal amphotericin B and caspofungin for this indication. 11, 16 Overall, 25% of episodes remained unclassified, either because they lacked a host-specific criterion or because they presented with non-specific clinical or radiological signs, thus not satisfying EORTC/MSG criteria. This work shows that, in practice, patients who do not fit into any of the classical categories make up a significant proportion of patients who receive antifungal therapy, indicating that in the physicians' opinion there is some ground to suspect an IFD. Whether such an approach should be considered as an empirical therapy similarly to the treatment of a febrile neutropenia, or as a pre-emptive therapy similarly to the treatment of a possible IFD, remains debatable. In our study, most of the patients treated for an unclassified episode received liposomal amphotericin B or caspofungin, in proportions similar to those for the group of patients with febrile neutropenia.
The IFD criteria revised in 2008 by the EORTC/MSG consensus group are more stringent than the criteria published in 2002, 12 -14 excluding from the possible IFD group cases with minor or nonspecific clinical signs such as cough, dyspnoea and pleural rub. All (day 7) 119 (28) 105 (25) 81 (19) 69 (16) 4 (1) 35 (8) 10 (2) 423 (100) Data are n (%) of episodes.
a One patient had both a proven other IFD and a probable aspergillosis and has been classified in the group 'Probable/proven other IFD' for all analyses. While the appropriateness of the updated 2008 criteria is recognized for patient inclusion in clinical trials, these criteria were never intended for guiding initiation (or not) of antifungal therapy in clinical practice. 13 It is therefore not surprising that clinicians started antifungal therapy in a significant set of patients not fulfilling the definitions of possible, probable or proven IFD.
Interestingly, 9% (10/107) of the episodes that were unclassified at day 0 were documented as possible, probable or proven Two patients died before day 7: one with an unclassified episode, the other with probable aspergillosis. c Combined treatments include 40 cases where antifungal prophylaxis was not immediately stopped upon introduction of a non-prophylactic treatment. In nine of these cases, prophylaxis was continued after day 7. d All but palliative treatment had been stopped for this patient, who died shortly after day 7.
IFD by day 7. Nine additional episodes, still unclassified at day 7, were documented as probable or proven IFD beyond day 7. Additionally, the 12 week mortality rate in those who remained unclassified at day 7 was very close to that observed in patients with possible IFD. The heterogeneity of this group shows, nevertheless, that in some patients, mycological confirmation of an IFD came after day 7, while in others antifungal therapy was discontinued early, indicating that suspicion seemed no longer justified.
Although providing interesting information on patients receiving antifungals in haematology wards, our study has some limitations, mainly due to its design. We collected data only on patients who, at inclusion, were receiving antifungals. Therefore, we cannot provide reliable incidence rates of IFD in the whole population of the participating wards. Additionally, inclusions may not have been consecutive, as some investigators may have hesitated to include the less founded suspicions, resulting in an underestimated rate of early treatment. This may partly explain the fairly high relative frequency of proven or probable IFD (21%) compared with other series. Conversely, they may have been reluctant to request consent from a dying patient and include the most serious cases.
The same design issues may account for the low mortality rate observed in this study. More than 80% of patients with probable or proven invasive aspergillosis were alive at week 12. This result seems in line with the decrease in IFD mortality observed over the last 10 years, 7,17 -19 although caution should be exerted in comparing studies performed in overlapping but not strictly similar patient populations. The low number of deaths observed in this work did not allow for a conclusive analysis of mortality risk factors for each subgroup. However, mortality in the whole patient population was, as shown in other studies, dependent on age and complete remission of the underlying haematological disease. 20 -23 Overall, in this comprehensive sample of haematological patients receiving antifungal treatment, we observe a widespread resort to early therapy, as already noted in a recent report, 7 and a low mortality rate, including in patients with probable or proven IFD.
